Compare Boston Scientific Corporation (BSX) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Logitech International SA — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Logitech International SA trades at $100.72 (market cap $14.53B). The key difference: Boston Scientific Corporation is far larger — about 4.6× Logitech International SA's market cap, and Logitech International SA pays a 1.69% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | LOGI | |
|---|---|---|
Market Cap | $66.37B | $14.53B |
Sector | Health | Technology |
52-Week High | $108.14 | $126.69 |
52-Week Low | $42.63 | $85.84 |
Enterprise Value | $75.94B | $12.88B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Logitech (LOGI) trades at $102.22, up 0.26% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a net margin of 14.69% and ROE of 32.78%, while recent quarters show consistent earnings beats. New product launches and a partnership with Call of Duty: Modern Warfare 4 highlight ongoing growth initiatives. Cash flow trends remain positive with 2026 operating cash flow projected at $1.0 billion.
Outlook is cautiously optimistic given mixed analyst ratings but solid fundamentals. Upside exists to the $113 consensus target, though competitive pressures and reliance on consumer spending pose risks. The stock offers value if execution on B2B and AI products drives margin expansion as anticipated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
